期刊
CELL PROLIFERATION
卷 54, 期 9, 页码 -出版社
WILEY
DOI: 10.1111/cpr.13102
关键词
angiogenesis; anti-angiogenesis; osteosarcoma; sarcoma; targeted therapy; VEGF
类别
资金
- National Natural Science Foundation of China [81960768]
- Natural Science Foundation of Guangxi Province [2019JJA140408]
- Youth Science and Technology Project of the First Affiliated Hospital of Guangxi Medical University [201903038]
- Creative Research Development Grant from the First Affiliated Hospital of Guangxi Medical University
- Abbie Basson Sarcoma Foundation Ltd
- Australian National Health and Medical Research Council (NHMRC) [1107828]
Osteosarcoma is the most common primary malignant bone tumor, with incidence peaking during adolescence. Despite improvements in prognosis with the introduction of neoadjuvant chemotherapy, outcomes have not significantly improved since then. Novel therapeutic strategies are urgently needed as an adjunct to conventional treatment modalities to improve outcomes for patients with osteosarcoma.
Osteosarcoma (OS) is the most common primary malignant bone tumour with a peak in incidence during adolescence. Delayed patient presentation and diagnosis is common with approximately 15% of OS patients presenting with metastatic disease at initial diagnosis. With the introduction of neoadjuvant chemotherapy in the 1970s, disease prognosis improved from 17% to 60%-70% 5-year survival, but outcomes have not significantly improved since then. Novel and innovative therapeutic strategies are urgently needed as an adjunct to conventional treatment modalities to improve outcomes for OS patients. Angiogenesis is crucial for tumour growth, metastasis and invasion, and its prevention will ultimately inhibit tumour growth and metastasis. Dysregulation of angiogenesis in bone microenvironment involving osteoblasts and osteoclasts might contribute to OS development. This review summarizes existing knowledge regarding pre-clinical and developmental research of targeted anti-angiogenic therapy for OS with the aim of highlighting the limitations associated with this application. Targeted anti-angiogenic therapies include monoclonal antibody to VEGF (bevacizumab), tyrosine kinase inhibitors (Sorafenib, Apatinib, Pazopanib and Regorafenib) and human recombinant endostatin (Endostar). However, considering the safety and efficacy of these targeted anti-angiogenesis therapies in clinical trials cannot be guaranteed at this point, further research is needed to completely understand and characterize targeted anti-angiogenesis therapy in OS.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据